JP7030345B2 - 眼の状態を処置する組成物および方法 - Google Patents

眼の状態を処置する組成物および方法 Download PDF

Info

Publication number
JP7030345B2
JP7030345B2 JP2019538106A JP2019538106A JP7030345B2 JP 7030345 B2 JP7030345 B2 JP 7030345B2 JP 2019538106 A JP2019538106 A JP 2019538106A JP 2019538106 A JP2019538106 A JP 2019538106A JP 7030345 B2 JP7030345 B2 JP 7030345B2
Authority
JP
Japan
Prior art keywords
compound
formula
eye
composition
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019538106A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533016A5 (cg-RX-API-DMAC10.html
JP2019533016A (ja
Inventor
バジル リーガス，
Original Assignee
メディコン ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メディコン ファーマシューティカルズ，インコーポレイテッド filed Critical メディコン ファーマシューティカルズ，インコーポレイテッド
Publication of JP2019533016A publication Critical patent/JP2019533016A/ja
Publication of JP2019533016A5 publication Critical patent/JP2019533016A5/ja
Application granted granted Critical
Publication of JP7030345B2 publication Critical patent/JP7030345B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/093—Polyol derivatives esterified at least twice by phosphoric acid groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2019538106A 2016-09-28 2017-09-28 眼の状態を処置する組成物および方法 Active JP7030345B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662400955P 2016-09-28 2016-09-28
US62/400,955 2016-09-28
US201762564595P 2017-09-28 2017-09-28
PCT/US2017/054051 WO2018064354A1 (en) 2016-09-28 2017-09-28 Compositions and methods for treating ophthalmic conditions
US62/564,595 2017-09-28

Publications (3)

Publication Number Publication Date
JP2019533016A JP2019533016A (ja) 2019-11-14
JP2019533016A5 JP2019533016A5 (cg-RX-API-DMAC10.html) 2020-11-12
JP7030345B2 true JP7030345B2 (ja) 2022-03-07

Family

ID=61760847

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019538106A Active JP7030345B2 (ja) 2016-09-28 2017-09-28 眼の状態を処置する組成物および方法

Country Status (7)

Country Link
US (2) US11510931B2 (cg-RX-API-DMAC10.html)
JP (1) JP7030345B2 (cg-RX-API-DMAC10.html)
AU (2) AU2017336765B2 (cg-RX-API-DMAC10.html)
BR (1) BR112019006160A2 (cg-RX-API-DMAC10.html)
CA (1) CA3038528A1 (cg-RX-API-DMAC10.html)
MX (1) MX2019003623A (cg-RX-API-DMAC10.html)
WO (1) WO2018064354A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020536067A (ja) * 2017-09-28 2020-12-10 メディコン ファーマシューティカルズ，インコーポレイテッド 眼の状態を処置するための組成物および方法

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006249866B2 (en) 2005-05-26 2011-10-13 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
CN111135171B (zh) 2013-01-23 2023-09-08 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
CN108135737B (zh) 2015-06-06 2021-11-05 拨云生物医药科技(广州)有限公司 用于治疗翼状胬肉的组合物和方法
CN118724806A (zh) 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途
CN109152774A (zh) 2016-05-09 2019-01-04 奥尔德拉医疗公司 眼部炎性病症和疾病的组合治疗
BR112018074450A2 (pt) 2016-06-02 2019-03-19 Cloudbreak Therapeutics, Llc composições e métodos para a utilização de nintedanib para melhorar o sucesso da cirurgia do glaucoma
WO2018064354A1 (en) 2016-09-28 2018-04-05 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
CN111356451A (zh) 2017-10-10 2020-06-30 奥尔德拉医疗公司 炎性病症的治疗
WO2020018498A1 (en) * 2018-07-16 2020-01-23 Aldeyra Therapeutics, Inc. Cyclodextrin formulations
CN112714762A (zh) 2018-08-06 2021-04-27 奥尔德拉医疗公司 多晶型化合物及其用途
WO2020047197A1 (en) * 2018-08-29 2020-03-05 Ocugen, Inc. Ophthalmic compositions and methods of use
CN113056353B (zh) 2018-09-25 2022-11-01 奥尔德拉医疗公司 用于治疗干眼病的调配物
ES2990204T3 (es) * 2018-10-19 2024-11-29 Univ Minnesota Procedimientos de aislamiento y utilización de la membrana de Descemet y composiciones que incluyen membrana de Descemet aislada
KR102151051B1 (ko) * 2019-01-10 2020-09-02 고려대학교 산학협력단 당뇨병성 백내장 치료 또는 예방용 조성물
US11786518B2 (en) 2019-03-26 2023-10-17 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
CN113784954A (zh) 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
BR112021026662A2 (pt) * 2019-09-10 2022-04-12 Cloudbreak Therapeutics Llc Métodos para aliviar a preocupação associada à pterígio sobre a aparência do olho
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
WO2022031830A1 (en) * 2020-08-04 2022-02-10 Harrow Ip Llc Antibacterial compositions and methods for fabricating thereof
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
EP4288151A4 (en) 2021-02-03 2025-01-01 ADS Therapeutics LLC Topical ophthalmological compositions
US11213551B1 (en) 2021-04-05 2022-01-04 Korb Research, Llc. Ocular treatment compositions and methods of use thereof
RS64402B1 (sr) * 2021-05-24 2023-08-31 Medicon Pharmaceuticals Inc Lečenje bola povezanog sa dijabetičkom perifernom neuropatijom
PL4114403T3 (pl) 2021-05-24 2023-10-09 Medicon Pharmaceuticals, Inc. Leczenie bólu neuropatycznego towarzyszącego neuropatii obwodowej indukowanej przez chemioterapię
AU2023273823A1 (en) * 2022-05-18 2024-12-05 Glaukos Corporation Novel applications of zwitterions in ophthalmic topical cream compositions and preparations
WO2025111079A1 (en) 2023-11-21 2025-05-30 Medicon Pharmaceuticals, Inc. Isomers of phosphosulindac
WO2025176750A1 (en) 2024-02-23 2025-08-28 Heinrich-Heine-Universität Düsseldorf Dual targeting in a new class of active ingredients

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070299124A1 (en) 2006-01-25 2007-12-27 Ousler George W Iii Formulations and methods for treating dry eye
JP2010535817A (ja) 2007-08-10 2010-11-25 リーガス，バジル 抗炎症性化合物とその用途
US20120295979A1 (en) 2011-05-03 2012-11-22 Florida Atlantic University Use of sulindac for protecting retinal pigment epithelial cells against oxidative stress
US20130225529A1 (en) 2012-02-27 2013-08-29 Basil Rigas Phospho-ester derivatives and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US4309566A (en) 1979-11-05 1982-01-05 Fmc Corporation Plant regulator
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
AU684950B2 (en) 1994-05-06 1998-01-08 Alcon Laboratories, Inc. Use of vitamin E tocopheryl derivatives in ophthalmic compositions
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
RU26988U1 (ru) 2002-05-06 2003-01-10 Закрытое акционерное общество "ДУКС-ЛИЗИНГ" Кондуктор для сверления отверстий
US20080153746A1 (en) 2004-04-06 2008-06-26 Transmolecular, Inc. Diagnosis and Treatment of Myeloid and Lymphoid Cell Cancers
CN1976692B (zh) 2004-06-23 2011-05-25 矫正诊疗公司 用视黄基衍生物治疗眼部疾病的方法和组合物
CN101754748A (zh) 2007-05-24 2010-06-23 阿西克斯医疗公司 治疗干眼症的制剂和方法
CA2885740A1 (en) 2012-09-21 2014-03-27 Basil Rigas Compounds and compositions for use in the prevention and treatment of inflammation-related disorders, pain and fever, skin disorders, cancer and precancerous conditions thereof
US20160051526A1 (en) 2013-04-09 2016-02-25 Cresset Biomolecular Discovery Ltd The Local Treatment of Inflammatory Ophthalmic Disorders
WO2018064354A1 (en) 2016-09-28 2018-04-05 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
CA3077033A1 (en) 2017-09-28 2019-04-04 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070299124A1 (en) 2006-01-25 2007-12-27 Ousler George W Iii Formulations and methods for treating dry eye
JP2010535817A (ja) 2007-08-10 2010-11-25 リーガス，バジル 抗炎症性化合物とその用途
US20120295979A1 (en) 2011-05-03 2012-11-22 Florida Atlantic University Use of sulindac for protecting retinal pigment epithelial cells against oxidative stress
US20130225529A1 (en) 2012-02-27 2013-08-29 Basil Rigas Phospho-ester derivatives and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020536067A (ja) * 2017-09-28 2020-12-10 メディコン ファーマシューティカルズ，インコーポレイテッド 眼の状態を処置するための組成物および方法

Also Published As

Publication number Publication date
AU2017336765A1 (en) 2019-04-18
US11510931B2 (en) 2022-11-29
AU2023226711A1 (en) 2023-09-21
BR112019006160A2 (pt) 2019-06-18
US20230293557A1 (en) 2023-09-21
MX2019003623A (es) 2019-09-23
WO2018064354A1 (en) 2018-04-05
US20190343848A1 (en) 2019-11-14
JP2019533016A (ja) 2019-11-14
CA3038528A1 (en) 2018-04-05
AU2017336765B2 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
US20230293557A1 (en) Compositions and methods for treating ophthalmic conditions
KR102675246B1 (ko) 안과적 병태를 치료하기 위한 조성물 및 방법
JP5421272B2 (ja) 眼病治療のための組成物及び方法
JP7116490B2 (ja) 眼の炎症性障害および疾患の組合せ処置
JP7669326B2 (ja) 局所製剤およびその使用
CN110290835B (zh) 用于治疗眼科病况的组合物和方法
JP2026035663A (ja) 高分子量ヒアルロン酸の眼科用薬物輸送ビヒクルとしての使用
KR20260051057A (ko) 안과용 활성제의 전달을 위한 조성물 및 방법
TWI809304B (zh) 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
US20240166691A1 (en) Prodrugs and compositions for ophthalmology applications
HK40014113A (zh) 用於治疗眼科病况的组合物和方法
HK40012460B (en) Compositions for treating ophthalmic conditions
HK40012460A (en) Compositions for treating ophthalmic conditions
Gaballa et al. Non‐Steroidal Anti‐Inflammatory Drugs (NSAIDs): Ocular Pharmacology, Pharmaceutical Innovations, and Drug Delivery Perspectives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200925

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220215

R150 Certificate of patent or registration of utility model

Ref document number: 7030345

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250